Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Growth in $21 Billion Molecular Diagnostics Market


There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition, a recent report added to the firm’s Knowledge Center subscription. The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).

THE IMPACT OF COVID-19

As the COVID-19 crisis surfaced in the United States, molecular diagnostic manufacturers went to work with new RT-PCR testing kits. So what can we expect for the future? As mentioned, molecular is already a roughly $10 billion market without COVID-19. While it’s possible COVID-19 tests will continue to be panelized and added to larger menus and may not have the emergency system sales of its 2020-2021 crescendo, its influence should last in other ways. It already has boosted the respiratory and healthcare infection molecular testing markets.

Kalorama Information estimates a $11 billion dollar market for 2022 for COVID-19 molecular diagnostics testing. Most of the larger companies already participating in the IVD market have products. The worldwide demand for molecular COVID tests grew to around $20 billion in 2021 and then began to rapidly decrease in Q2 2022 and into Q3 2022.

INFECTIOUS DISEASES AND OTHER KEY AREAS OF FUTURE GROWTH

The dominance of the COVID-19 segment arguably isn’t surprising considering that the first category where molecular diagnostics earned their place was infectious disease. In this category, specific results were needed for treatment decisions. The pioneers in the molecular diagnostics field included Roche Diagnostics, Gen-Probe, and Becton Dickinson.

“The main focus of the initial molecular diagnostics products was infectious diseases including HIV, Chlamydia trachomatis, Neisseria gonorrhoeae, and tuberculosis. These diseases are still critical components of the market,” says Bruce Carlson, vice president of publishing at Kalorama Information, a division of Science and Medicine Group. “Recent growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas.”

Beyond COVID-19, growth areas forecast over the next five years will be led by sexually transmitted infection testing, but will include other areas of focus, specifically:


  • STIs
  • Hepatitis
  • Respiratory
  • Tuberculosis
  • Cancer assays (blood)
  • Molecular human papilloma virus (HPV)
  • Pharmacogenomics

ABOUT THE REPORT

For more information purchase “The World Market for Molecular Diagnostics Tests, 11th Edition,” available at: https://kaloramainformation.com/product/the-world-market-for-molecular-diagnostics-tests-11th-edition/.

Kalorama Information’s 11th edition report of the clinical molecular testing industry provides marketing sizing and forecasts for in vitro diagnostics (IVDs) over a five-year period. In this report, our industry experts and top analysts assess the current positions of this complex, multi-billion dollar market. This data publication has become an indispensable tool in clinical healthcare medicine and assesses the business opportunity, new product introductions, and rapid changes in several areas of this industry, including:

  • Infectious Disease Molecular Diagnostics (COVID-19, Hepatitis, HIV, Respiratory, STI, Others)
  • Cancer Molecular Diagnostic Markets (Blood-based and Tissue-based)
  • Genetic Molecular Diagnostic Markets (SNPs, Inherited, NIPT, Other)
  • Blood Banking Molecular Diagnostics Markets
  • Transplantation Molecular Diagnostic Markets
  • Regional Molecular Diagnostics Markets (North America, Europe, Asia, Global)

ABOUT KALORAMA INFORMATION

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Becker ENT Now Serving the Areas of East Windsor and West Windsor


Becker ENT Now Serving the Areas of East Windsor and West Windsor

Becker ENT Now Serving the Areas of East Windsor and West Windsor

Becker ENT & Allergy offers a full range of services, including medical and surgical treatment of conditions affecting the ears, nose, throat, and related structures of the head and neck. Board-certified physicians are experts in the latest ENT treatments and technologies and are committed to providing each patient with individualized care.

Becker ENT & Allergy is now serving the areas of East Windsor and West Windsor! This expanded access to medical and surgical services means that residents of these communities can now receive the highest quality care for all their ENT needs.

For more information, please visit: https://www.beckerentandallergy.com/

We all need clear sinuses for free and easy breathing. Inflamed or blocked sinuses can cause difficulty breathing, congestion, and sometimes pain. Many people suffer from chronic sinusitis or recurring sinus infections, which can interfere with sleep, work performance, and quality of life.

Becker ENT Specializes In:

Sinusitis

Becker ENT investigates the root cause of sinusitis to determine whether it is acute or chronic and identify the best treatment options. In some cases, sinusitis can be caused by structural problems in the nose or sinuses, such as a deviated septum. In these cases, surgery may be recommended to improve airflow and drainage. However, in other cases, less invasive treatments such as medication or irrigation may be all that is needed to relieve symptoms. Becker ENT otolaryngologists treat each patient with the utmost compassion and respect.

Otolaryngology

Head and neck surgery is a subspecialty of otolaryngology that deals with the surgical treatment of head and neck disorders. The head and neck include the sinuses, larynx (voice box), oral cavity, pharynx (throat), and face and neck structures.

Otolaryngologists at Penn Medicine Becker ENT & Allergy work as a team to determine what is causing a patient’s head and neck issues and devise a personalized plan to fix them. Often, problems in these areas are caused by thyroid or sleep apnea problems, while other times, it can be as serious as head and neck cancer. No matter the issue, otolaryngologists at Penn Medicine Becker ENT & Allergy are here to help.

Sleep Apnea

Another issue is sleep apnea. This occurs when breathing is interrupted during sleep. This can happen because of obstruction in the airway or a problem with the brain signals that control breathing. Sleep apnea can lead to fragmented sleep, which can cause daytime fatigue and impair work performance and quality of life. It can also strain the heart and increase the risk of high blood pressure, stroke, and heart attack.

Becker ENT physicians treat sleep apnea with various methods, depending on the underlying cause. Surgery may sometimes be recommended to remove blockages in the airway. However, other treatment options include lifestyle changes, such as losing weight or sleeping on your side and using a continuous positive airway pressure (CPAP) machine. In some cases, an oral appliance or antihistamine may be enough to ease symptoms. Becker ENT sleep specialists will work with you to determine the best course of treatment.

For information relating to services offered in Robbinsville, please visit: https://www.beckerentandallergy.com/locations/robbinsville-nj-ent-doctor

Hearing Aid Evaluation

Becker ENT now offers hearing aid evaluation to East Windsor and West Windsor residents. Audiologists on staff offer comprehensive testing and counseling services to patients of all ages. They also dispense and fit hearing aids and provide ongoing support to patients as they adjust to life with hearing loss.

Ear Infections & Hearing Loss

ENT professionals commonly treat chronic ear infections, perforations, wax buildup, and eustachian tube dysfunction. If you or a loved one is experiencing hearing loss, the first step is to schedule a hearing test. This will help to determine the extent of the loss and what type of treatment will be most effective for better hearing. In many cases, hearing loss solutions such as hearing aids can significantly improve the quality of life.

Allergies

Allergies occur when the immune system reacts to a harmless substance as if it were a threat. This can cause various symptoms, including watery eyes, a runny nose, hives, and anaphylaxis. Many people suffer from seasonal allergies when pollen is released into the air. Others may have allergies to specific foods, such as peanuts or tree nuts. If you think you or your family members may have allergies, immunotherapy may be a good option to help manage symptoms. Allergy shot drops or other treatments may be appropriate.

Meet The Doctors

Dr. Robert Mignone, DO, and Dr. Omar Ahmed, MD

Dr. Robert Mignone and Dr. Omar Ahmed are highly trained, board-certified otolaryngologist-head and neck surgeons at Penn Medicine Becker ENT & Allergy.

While taking a special interest in upper airway disorders, Dr. Mignone practices all aspects of otolaryngology. This includes allergy/sinus disease, sleep apnea, thyroid/parathyroid, and other head and neck disorders. After medical school, he completed a residency in Otolaryngology-Head & Neck Surgery and Facial Plastic Surgery and also had training at Memorial Sloan-Kettering Cancer Center. Dr. Mignone sees both adults and children.

Dr. Ahmed specializes in Ear, Nose, and Throat disorders. His advanced fellowship training in minimally invasive sinus and skull base surgery gives him special expertise in medical and surgical treatments of sinus and nasal conditions. He is a well-established speaker and has authored many scientific articles.

Dr. Kathryn Edwards, MD

Dr. Kathryn Edwards is a highly trained, board-certified Allergist and Immunologist. After joining the United States Army and becoming a Board-Certified Pediatrician, she spent many years deployed in Iraq serving military families and those in need. Dr. Kathryn Edwards specializes in the diagnosis and treatment of allergies including seasonal, environmental, and food allergies. She also treats a variety of skin conditions including hives, eczema, and asthma.

For information relating to Allergy & Hearing Loss Services, please visit: https://www.beckerentandallergy.com/

The expert allergists and immunologists at Penn Medicine Becker ENT can offer testing, reconstructive surgery, and long-term care for all ages suffering from allergy and asthma symptoms.

Becker ENT is a medical specialty that diagnoses and treats the abovementioned conditions. For ENT services in East Windsor and West Windsor, look no further than Becker ENT to provide the best possible care for patients of all ages.

Contact

Organization: Penn Medicine Becker ENT & Allergy

Website: https://www.beckerentandallergy.com/contact

Location: 256 Bunn Drive, Suite A

Princeton, NJ 08540

Phone: (609) 354-5445 | Get Directions

Intercepting Science for Health in 2023!


People nowadays are looking for a secret to slimming down and achieving an ideal shape. Celebrities like Elon Musk, Kim Kardashian and many others have found a solution – Semaglutide!

Losing weight is hard, but Nextmed makes it a little bit easier with science. With an ever-growing selection of prescription weight loss medications, Nextmed provides an online resource for people looking to start their journey to a healthier lifestyle. Check NextMeds today to get amazing offers on their Holiday Sale where you pay only $99 on all programs.

The commitment extends to provide the best possible service and care as an Online Weight Loss Clinic.

Conquer your new year those weight loss goals with Online Weight Loss Clinics and ensure you do it right this time!

With health goals becoming easily achievable yet affordable, isn’t it a great innovative Weight Loss Medication Online with excellent value? Don’t miss out on this fantastic breakthrough- tighten the belt, or shrink those love handles.

For those with goals of adding something new to the weight loss routine, there are programs out there offering great value (even for Type-2 diabetes patients). Ozempic & Wegovy are injectable drugs based on Semaglutide. They can be taken once weekly at up to 2.4 mg doses [FDA-approved], specially designed so individuals can reach their health goals more effectively.

For instance, if someone has a high BMI and struggles with diet and exercise but still hasn’t achieved that desired weight-loss goals, this revolutionary medicine can significantly help.

But before getting into it- there are three things to be kept in mind for the successful usage of Weight Loss Medication Online: no alcohol during treatment, a detailed history free from any past pancreatitis events (inflammation), and lastly, making sure gall stones don’t impair effectiveness. This life-changing solution is here now – let’s begin.

How Wegovy Can Help Shed Those Unwanted Pounds

Wegovy is a newly approved prescription weight-loss medication that stimulates certain hormones in the brain to control appetite, which helps users feel full longer and therefore eat less.

The main benefit of using Wegovy for weight loss is its effectiveness. While diet and exercise remain the best way to lose weight, this medication can offer additional support. This can be a godsend for many people who struggle with their diets or cannot exercise due to medical issues or other circumstances.

Additionally, because it only needs to be taken once a week as opposed to daily like most other medications, it’s easier for users to stay consistent with their dose and maintain their progress towards their goals.

Another benefit of using Wegovy medication online is its safety profile. Unlike other weight loss medications, Wegovy reviews prove that one has no known side effects or risks associated with long-term use.

A popular tool to tackle obesity & attain those weight loss goals, Wegovy has lot more to offer and explore! Consult NextMed team now & enter the weight loss revolution!

Share article on social media or email:

Removing Socioeconomic Barriers and Increasing Diversity in Clinical Trials Would Have a Positive Economic Impact


News Image

Between logistical burdens, distrust in the healthcare system, and lack of awareness and information in many non-English languages, key demographic groups like women, children, low-income households, and racial and ethnic minorities are effectively left out of clinical trials.

Clinical trials have a failure rate of 30% because they cannot meet their target patient enrollment, which is often caused by a lack of diversity in clinical trial candidates. This results in setbacks in 85% of clinical trials causing biopharmaceutical sponsors to lose $600K to $8M for each day a trial is delayed.(1) Limited representation and inclusion of a diverse population in clinical trials have far-reaching consequences by skewing clinical trial results, leading to poorer health outcomes and premature deaths among the U.S. population. Jeeva Informatics is the leading human-centric eClinical platform seeking to accelerate patient recruitment and retention by being champions of diversity, equity, and inclusion in clinical trials through decentralization and reducing socioeconomic barriers to healthcare.

“Recruitment for clinical trials is severely broken,” explains Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics. He notes, “Between logistical burdens, distrust in the healthcare system, and lack of awareness and information in many non-English languages, key demographic groups like women, children, low-income households, and racial and ethnic minorities are effectively left out of clinical trials.” The Future Elderly Model developed by the USC Schaeffer Center found that if drug development using more representative clinical trials eliminated just 1% of these health disparities, it would result in significant gains for patients and society. The study further concluded that increased representation in clinical trials could save billions of dollars and improve the quality of life for millions of Americans.(2)

One out of four patients cites logistical burdens, such as access/cost of childcare, transportation, and loss of pay, as the primary reasons for not taking part in clinical trials. The vast majority of participants are Caucasian adult males from affluent backgrounds.(1) Patients with an annual household income of less than $50,000 have 32% lower odds of trial enrollment. Aside from financial challenges, other socioeconomic obstacles, such as a lack of insurance, limited job flexibility, and health illiteracy, contribute to a generalized apprehension regarding clinical trials.(3)

Regulatory agencies are now taking steps to encourage researchers to make diversity a focus. The FDA recently released its “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.” In it, they recommend financial reimbursement or compensation for expenses incurred, language assistance for participants with limited English language proficiency, and clinical trial sponsor enrollment goals for underrepresented racial and ethnic participants.(4)

In addition to saving billions of dollars and improving the health of all American citizens, improving diversity helps build trust between the pharmaceutical industry and the public, which has long been a strained relationship. Biopharmaceutical companies are forming partnerships with local communities and patient advocacy groups, offering financial support, and providing more convenient trial locations to help improve access, spread awareness, and build trust among more diverse populations.(5)

A decentralized trial model helps meet patients where they live and utilizes local community leaders to earn participants’ trust and make them feel more comfortable about the information. For Dr. Rajasimha, diversity has been a priority from day one. While regulatory bodies and researchers tout the benefits of diversity, the reality is harder to achieve and requires more time and resources. The traditional model of all in-person patient visits no longer works, and to achieve operational flexibility with reliable and accurate results, Dr. Rajasimha and his team developed the modular Jeeva™ eClinical Cloud by leveraging stakeholder inputs over the last few years. This human-centric and empathetic platform accelerates clinical research timelines over 3x faster.

With bi-directional communications, activity scheduling, eligibility screening, and remote touchless electronic informed consent, investigators can educate and enroll participants safely from their own mobile devices. Investigator teams can avoid repetitive tasks and save 70% of their time during enrollment. Dr. Rajasimha stresses, “It is imperative that, as an industry, we work to accelerate clinical trials to bring new medicines or vaccines to all patients, including historically underrepresented minorities, who need them, thus increasing the chances of survival. Our modular platform is fully scalable and facilitates diverse patient enrollment, engagement, retention, and evidence generation.”

About Jeeva Informatics

The personal experience of losing a child born with a rare disease and a brother with a chronic disease became the springboard for Dr. Harsha Rajasimha to apply his years of postdoctoral training at NIH and FDA to accelerating therapies for rare and common conditions. He knew that technology in itself is not the limiting factor and that patient-centered design guided by stakeholder needs and regulatory requirements would guide their continuous learning digital platform. By digitizing and automating manual repetitive tasks and reducing the logistical burdens on patients and study teams by over 70%, Jeeva accelerates the process of bringing new medicines or vaccines to patients who need them by over 3x faster. The Virginia-based company’s modular software-as-a-service platform is fully scalable and facilitates patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device. Visit https://jeevatrials.com/.

References

1. Frank Sasinowski, MPH. “Jeeva – Accelerate Clinical Research, Maximize Patient Diversity.” Decentralized Clinical Research Software as a Service, jeevatrials.com/.

2. Goldman, Dana, et al. “Lack of Diversity in Clinical Trials Costs Billions of Dollars. Incentives Can Spur Innovation.” USC Schaeffer, 30 Sept. 2022, healthpolicy.usc.edu/article/lack-of-diversity-in-clinical-trials-costs-billions-of-dollars-incentives-can-spur-innovation/.

3. Price, Kyla N., et al. “Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients.” Dermatology, Karger Publishers, 15 Dec. 2020, karger.com/Article/FullText/511889.

4. “FDA Guidance on Diversity Plans in Clinical Trials: What You Need to Know.” Bass, Berry & Sims PLC, bassberry.com/news/diversity-plans-clinical-trials/.

5. “Achieving Clinical-Trial Diversity Requires Trust, Awareness, Access.” Deloitte United States, 2.deloitte.com/us/en/blog/health-care-blog/2022/achieving-clinical-trial-diversity-requires-trust-awareness-access.html.

Share article on social media or email:

Mouaz H. Al-Mallah, MD, MSc, FASNC, Installed as ASNC’s President for 2023


Mouaz Al-Mallah, MD, MSc, FASNC, 2023 ASNC President

Mouaz Al-Mallah, MD, MSc, FASNC, 2023 ASNC President

“These enhancements to nuclear cardiology imaging are making it possible for us to see more. The more we see, the more we understand, and the better we can serve our patients.” – Mouaz H. Al-Mallah, MD, MSc, FASNC

Mouaz H. Al-Mallah, MD, MSc, FASNC, director of the cardiovascular PET program at the Houston Methodist DeBakey Heart and Vascular Center, was installed as president of the American Society of Nuclear Cardiology (ASNC) for 2023. Dr. Al-Mallah is also the Beverly B. and Daniel C. Arnold distinguished chair and professor of cardiology at the Houston Methodist Academic Institute and a professor of medicine at Weill Cornell Medicine. He launched his term with a President’s Message encouraging nuclear cardiologists to “broaden their horizon” by adopting the “significant innovations” the field has realized over the past decade.

“Nuclear cardiology imaging remains at the center stage in the era of multimodality testing,” Dr. Al-Mallah says. “We also have an exciting array of new technologies and other innovations available to enhance our diagnostic abilities and serve our patients even better. This is especially important now, considering the global prevalence of diabetes and obesity.”

Recent innovations in nuclear cardiology include –

  • New cameras, radiopharmaceuticals and artificial intelligence tools;
  • Technological advances, such as cardiac PET, hybrid imaging and myocardial blood flow quantitation; and
  • Rapidly expanding applications for nuclear cardiology imaging in areas including amyloid, inflammation and infection.

“These enhancements to nuclear cardiology imaging are making it possible for us to see more,” Dr. Al-Mallah says. “The more we see, the more we understand, and the better we can serve our patients.”

His President’s Message outlines a strategy that nuclear cardiology teams should follow for modernizing their labs with the field’s newer innovations as well as resources for learning how to use the new applications to optimize patient care.

Dr. Al-Mallah earned his medical degree from the American University of Beirut in Lebanon. He completed his internal medicine residency and cardiovascular training fellowships at Henry Ford Hospital, Wayne State University and at the Brigham and Women’s Hospital-Harvard Medical School. He also obtained a master’s degree in clinical research design and biostatistics at the University of Michigan at Ann Arbor.

He has been recognized with several awards for excellent teaching and his research, which has focused on the prognostic value of nuclear cardiology, cardiac PET, cardiac CT and coronary calcium scores and on the use of advanced cardiac imaging for risk prediction, patient management and outcomes. He has published more than 450 articles and book chapters.

Dr. Al-Mallah has been an active member of ASNC since joining in 2005. Most recently, he served as the lead author on the 2022 ASNC/AAPM/SCCT/SNMMI Guideline for the Use of CT in Hybrid Nuclear/CT Cardiac Imaging. He has been the program director for ASNC’s Intensive and Advanced Cardiac PET Workshops as well as for ASNC/Saudi Heart Association Nuclear Cardiology Now: Middle East. On Jan. 17, Dr. Al-Mallah will moderate ASNC’s webinar Private Equity: Impact on Nuclear Cardiology and Lab Modernization.

Dr. Al-Mallah will lead ASNC’s 2023 Executive Council, which also includes President-elect Lawrence Phillips, MD, FASNC; Vice President Panithaya Chareonthaitawee, MD; Secretary Karthikeyan Ananthasubramaniam, MD, FASNC; Treasurer Jamieson Bourque, MD, MHS, FASNC; Immediate Past President Dennis A. Calnon, MD, MASNC; and Once-removed Past President Randall C. Thompson, MD, MASNC.

###

About the American Society of Nuclear Cardiology

For more than 25 years, the American Society of Nuclear Cardiology and its more than 4,900 members have been improving cardiovascular outcomes through image-guided patient management. As the only society dedicated solely to the field of nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research development. ASNC provides peer-reviewed original articles through its official publication Journal of Nuclear Cardiology and operates the nation’s first noninvasive cardiac imaging registry, ImageGuide Registry®, to benchmark quality and improve patient care. For more information, visit http://www.asnc.org.

Share article on social media or email:

NOWATCH, World’s First “Awareable” that Helps Wearers Estimate and Eliminate Sustained Stress


NOWATCH, a screenless watch that provides real-time feedback about movement, sleep and stress, alongside recovery tools to restore balance and help users to live more fully in the “now”

“People worldwide are more stressed than ever. NOWATCH is a simple, yet powerful tool to help people stay grounded in the present, reminding us there’s no time like the present and there is only NOW,” said NOWATCH CEO and founder, Hylke Muntinga.

NOWATCH, a health innovation company and creator of the “awareable” category, will premiere a screenless watch at CES 2023 that provides real-time feedback about movement, sleep and stress, alongside recovery tools to restore balance and help users to live more fully in the “now.” NOWATCH helps to break the cycle of overstimulation, anxiety and stress, liberates the wearer from ‘always-on’ culture, increases mindfulness and opens them up to the potential of every moment. NOWATCH will showcase its technology at CES Unveiled Las Vegas on January 3, 2023, and at CES 2023 from January 5 – 8, 2023, at the Venetian Expo, Eureka Park, Hall G, Booth 62100. View a short video about NOWATCH here.

NOWATCH CEO and co-founder Hylke Muntinga discovered in 2019 that he carries a rare genetic condition, PXE, which will ultimately cost him his eyesight. Inspired by his diagnosis and his desire to help people get the most out of every moment,, he created NOWATCH in partnership with his co-founder, Timothée Manschot and Philips. “People are more stressed than ever and need simple but powerful solutions that help them stay mindful of their emotions and health,” said Muntinga. “NOWATCH is easy to use so it doesn’t become another distraction or obstacle for the wearer, and is a powerful tool to help people stay grounded in the present and achieve well-being. NOWATCH reminds us all there’s no time like the present and there is only now.”

The screenless NOWATCH has a fashionable, interchangeable ethically-sourced gemstone face, and is powered by advanced health-tracking technology that quietly works as the wearer goes about their day. NOWATCH delivers gentle vibrations throughout the day that bring the wearer back to the present, reducing stress, increasing awareness and mindfulness, and ultimately helping to improve mental health and physical well-being.

How NOWATCH Works:

  • Philips EDA (Electrodermal Activity) Biosensing Technology: measures changes in sweat gland activity via skin conductance. The biosensing technology sends a small, non-harmful current to the skin and measures the change in electrical conductance between two points over time on the skin.
  • Stress Estimate: Is derived from skin conductance, which is a direct measure of the wearer’s sympathetic nervous system. Stress levels are measured across different levels: Calm (i.e., no stress, no reactivity), Very Low up to Very High.
  • Vibrations: NOWATCH quickly learns the wearer’s biorhythms and users can choose to send subtle vibrations to help them become aware of their stressors and emotions, inviting them to reconnect to the present and restore balance.
  • Predicted Cognitive Zone: Reflects the user’s cognitive performance (i.e. ability to think clearly) and gives the wearer time to intervene and self-correct if they choose. The wearer’s current physiology informs their predicted cognitive zone, which is viewable in the app momentum page of the NOWATCH app.
  • Mood: Tracks the wearer’s mood to help them better contextualize the fluctuations in their physiology. Data is also used to help enhance NOWATCH algorithms.
  • Individual Stress Fingerprint: By identifying their individual “stress fingerprint,” users are better able to recognize and manage their stress. NOWATCH enables users to discreetly capture and save specific moments when they are stressed by simply pressing the crown on their watch, which marks their physiology with a time stamp in the app and offers an option to add a journal entry to the moment.
  • In-app Breathing Exercises and Lifestyle Recommendations: Empower users to monitor and respond to stress and what triggers it, leading to greater awareness and understanding of their mental state.

According to the World Health Organization, stress is the number one health challenge of the 21st century. The American Psychological Association estimates stress related health problems cost the U.S. $300 billion annually. Mindfulness – which helps people focus on their breath, present moment awareness and relaxation – offers a simple, drug-free, repeatable way to improve mood, concentration and stress tolerance. NOWATCH allows users to tap into many of the benefits of mindfulness and chart their progression and physical health.

NOWATCH Features and Specifications:

  • Scientifically Estimates Stress Levels: Measures stress using Philips EDA (Electrodermal Activity) biosensing technology. The Stress Estimate is derived from skin conductance, categorized by different levels: calm (no stress/no reactivity), then a stress range from very low to very high.
  • Screenless by Design: Created screenless by design with interchangeable gemstones, NOWATCH encourages the user to experience the sensations they feel in the present moment — instead of adding another distraction.
  • Companion iOS and Android App: Displays the NOWATCH wearer’s physiology in real-time and provides actionable insights to help them live a more balanced life.
  • Technology: Bluetooth Low-Energy, EMF-safe, airplane mode compliant
  • Sensors: Red and green PPG (photoplethysmography), EDA, accelerometer, temperature and barometer
  • Dimensions: Length: 9.75” (24.7 cm) length x 1.46” (37 mm) diameter x 0.43” (10.9 mm) thick
  • Weight: 1.76 oz or 50 grams
  • Waterproof (5ATM) and Temperature-Resistant
  • Battery Life: Up to four full days depending on use
  • Special CES 2023 Pricing:
  • Starting at $369 USD / €369 Euros / £369 GBP
  • (MSRP starting at $499 USD / €499 Euros / £499 GBP as of January 9, 2023)
  • Includes:
  • Watch housing: stainless steel, silver, gold or rose gold/PVD coating
  • One magnetically interchangeable disc of choice: gemstone or metal
  • Choice of metal disc: stainless steel, silver, gold or rose gold
  • Lifetime subscription membership (CES special only): Subscribers receive a continuously growing suite of software features, data-driven insights, personalized recommendations, guided exercises and scientifically-backed educational content. (Regular price: three-year membership for $6/month; one-year for $9/month; or monthly for $12/month)
  • Pricing: Ethically-Sourced, Watch Face Gemstones (sold separately):
  • White Agate: $89
  • Tigers Eye: $49
  • Rose Quartz: $25
  • Malachite: $139
  • Lapis Lazuli: $219
  • Labradorite: $49
  • Falcon Eye: $49
  • Amethyst: $99
  • Watch Band Options:
  • 12 watch bands made from sustainable leather
  • Five watch bands made from 100% woven recycled ocean plastic
  • What’s in the Box:
  • Watch band
  • Watch housing
  • Interchangeable disc of choice
  • USB-C cable charger
  • Box Packaging: Made of recycled cork and mycelium; 100% sustainable and can be used for travel/storage
  • Where to Buy: NOWATCH website or NOWATCH flagship store located in the heart of Amsterdam at 455 Prinsengracht.
  • Launch Markets: U.S., Canada, Europe and U.K.

Interested media, industry partners and investors are invited to contact nowatch@wearemgp.com to schedule and appointment at CES to experience NOWATCH. Visit NOWATCH to learn more or access the NOWATCH press kit here.

About NOWATCH

NOWATCH is the world’s first “awareable,” a screenless designer watch that provides real-time feedback about movement, sleep and stress, as well as recovery tools to restore balance. NOWATCH uses Philips EDA (Electrodermal Activity) biosensing technology to measure changes in skin conduction, quickly learning biorhythms and making the wearer aware of their emotions and physiology. Featuring an interchangeable gemstone face, and delivering gentle vibrations throughout the day, NOWATCH brings the wearer back to the present, relieving stress, increasing mindfulness and ultimately improving mental and physical health.

Founded in 2020 by Hylke Muntinga and Timothée Manschot, NOWATCH is a pending B-corporation headquartered in Amsterdam and is a privately held company. Follow NOWATCH on Instagram, YouTube, Facebook, Twitter and LinkedIn or learn more at https://nowatch.com.

###

Share article on social media or email:



The AMA Presents a Framework for Measuring Telehealth Quality


News Image

Our vision is to support continuous monitoring in real-time to near real-time in hospital-to-home scenarios, that ensures complete data continuity with no compromises.

Under the simultaneous pressures of a pandemic-driven explosion in the use of telehealth, a growing emphasis on value-based care, and the current state of medical technology, the healthcare industry is undergoing what appear to be fundamental changes as a consequence of the high and irreversible growth of telehealth. The evolution of medical technology enables effective virtual care in the home for patients with increasingly serious conditions. Stuart Long, CEO of InfoBionic, observes, “One of the most important lessons we learned is that telehealth and virtual care are really important augmentations to our healthcare matrix, and they’re here to stay.” InfoBionic is pioneering the first virtual care, hospital-grade telemetry platform capable of supporting low- to high-acuity cardiac patients anywhere virtual care is delivered.

In December 2022, the American Medical Association (AMA), in partnership with Manatt Health, released the “Return on Health” report that develops a framework to more precisely and holistically measure the value of telehealth through detailed case studies. This initiative also focuses on the challenges and opportunities for virtual care.(1) The adoption of the latest technology is essential to the expansion of telehealth beyond routine patient care.

Long notes, “Where telehealth’s primary focus is on convenience, virtual care is focused on bringing the richness of healthcare to patients in a variety of settings, and harnessing technology to accelerate time to diagnosis and improve health outcomes. While the pandemic was an accelerator of this shift, cardiology was actually an early luminary in first demonstrating the value and potential of virtual models.”

Medicare visits conducted through telehealth increased 63-fold in one year, from approximately 840,000 in 2019 to 52.7 million in 2020. Though the Covid-19 pandemic primarily drove this increase, all indications are that extensive use of telehealth is now a permanent feature of the modern face of healthcare.(2) In 2021, 37% of adults in the United States used telehealth for appointments or communication with healthcare professionals.(3) After the initial adjustment period, providers and patients realized that the flexibility, convenience, and potential for cost savings make telehealth a valuable addition to the healthcare delivery system.

InfoBionic is developing a spectrum of devices capable of dealing with cardiology problems from the simplest to the most complex to create the hospital experience in a virtual-care world. InfoBionic’s MoMe ARC platform is remote monitoring designed for virtual cardiology. Long says, “Our vision is to support continuous monitoring in real-time to near real-time in hospital-to-home scenarios, that ensures complete data continuity with no compromises. We can monitor patients anywhere virtual care is delivered without missing a beat.”

Incorporating state-of-the-art remote patient monitoring technology within the virtual healthcare system can reduce the risk of avoidable hospital visits, extended stays, and readmissions. For every 500 high-risk Medicare patients with multiple chronic conditions, health systems can realize $5.2 million in annual cost savings.(4)

The emphasis of the AMA and Manatt framework for telehealth is not narrowly focused on cost savings; it measures the benefits of these additional value streams for healthcare providers and patients:(1)

1. Clinical outcomes, quality, and safety.

2. Access to care.

3. Patient and family experience.

4. Clinician experience.

5. Financial and operational impact.

6. Health equity.

Long remarks, “So, what’s next for virtual care? As providers navigate the new virtual care reality, cardiology is being called upon yet again to lead the way. What began as remote patient monitoring has been replaced by a powerful new model for virtual telemetry that enables high-integrity patient monitoring for a wide variety of virtual clinical use cases — from preventive care to advanced hospital-to-home scenarios.”

About InfoBionic

InfoBionic’s digital technology has transformed the efficiency and economics of cardiac remote patient monitoring. The company’s MoMe ARC platform vision is to remove the roadblocks hindering remote diagnosis and decision-making. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology and bring specific expertise in remote monitoring and cardiology. Visit https://InfoBionic.com/.

References:

1. “AMA Publishes Framework to Highlight Value of Virtual Care.” Healthcare IT News, 20 May 2021, healthcareitnews.com/news/ama-publishes-framework-highlight-value-virtual-care.

2. King, Robert. “HHS: Telehealth Use in Medicare Increased 63-Fold Last Year with Behavioral Health Increasing the Most.” Fierce Healthcare, 5 Dec. 2021, fiercehealthcare.com/practices/hhs-telehealth-use-medicare-increased-63-fold-last-year-behavioral-health-increasing-most.

3. “Products – Data Briefs – Number 445 – October 2022.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 12 Oct. 2022, cdc.gov/nchs/products/databriefs/db445.htm.

4. “How Remote Patient Monitoring Improves Care, Saves Money for Chronic Care.” Healthcare IT News, 13 July 2022, healthcareitnews.com/news/how-remote-patient-monitoring-improves-care-saves-money-chronic-care.

Share article on social media or email:

AYAVAYA Debuts Stress-Busting Cabin at CES 2023 that Helps Users Achieve Inner Calm within 20 Minutes


AYAVAYA, creator of the anti-stress cabin that eliminates stress in 20 minutes

“The AYAVAYA cabin has a powerful effect, provides instant stress relief — and when used repeatedly — offers stress resistance,” said AYAVAYA CEO and co-founder Jasper Momma. “AYAVAYA will help people worldwide rapidly eliminate their stress and recharge in 20 minutes.”

AYAVAYA, a healthtech company, today announced the debut of its patented, scientifically validated anti-stress cabin at CES 2023. The cabin brings users into a meditative state and eliminates stress within 20 minutes by combining four automated, non-invasive treatments. AYAVAYA invites press to mailto:ayavaya@wearemgp.com [book an appointment and experience the treatment __title__ null] first hand during CES 2023, January 5 – 8, at booth 62100, stand 35 at Eureka Park in the Venetian Expo. Watch a short video of how AYAVAYA works.

“The AYAVAYA cabin has a powerful effect, provides instant stress relief — and when used repeatedly — offers stress resistance,” said AYAVAYA CEO and co-founder Jasper Momma. “AYAVAYA will help people worldwide rapidly eliminate their stress and recharge in 20 minutes. It will also allow a range of businesses to help their employees, customers or guests take a break from an often challenging world and offer them additional ways for self-care. We believe we have succeeded in creating the most accessible, anti-stress tool available on the market.”

Features and benefits of the AYAVAYA anti-stress cabin:


  • Utilizes four automated, non-invasive, scientifically proven treatments to bring the user into a meditative state and eliminate stress, including: Shirodhara, a 5,000 year old Ayurvedic procedure in which warm water is projected onto the forehead with a specific pressure, flow, temperature and rhythm to induce a relaxed state of awareness that results in a dynamic psychosomatic balance; Sound therapy, 8D surround sound technology with Solfeggio binaural beats soundtracks cause a rapid recalibration of the brain to restore mental balance; Aromatherapy and Colored Light therapy that reinforces the meditation-inducing effects of the Shirodhara treatment.
  • A stand-alone device that doesn’t require operational guidance. Users don’t need to change clothes or do any exercises: they simply push a button and lie down in the cabin for a fully automated 20-minute treatment that is scientifically proven to induce deep meditation, regardless of the user’s prior knowledge of meditation practices.
  • Developed for use by people at offices, hotels, airports and airport lounges, hospitals, health spas, gyms, and therapist offices, while also making it affordable for these types of establishments to offer treatments at a low price, with low power and water consumption.
  • Retails for $25K, but is also available to lease at a cost of $750 per month for a three-year period, with no deposit required. The AYAVAYA cabin also yields a high ROI when offered as a treatment to paying customers: an average of eight treatments per day at a suggested cost of $15 per treatment against a lease of $750 per month nets a monthly profit of $1,650 per cabin.

Stress reduction is one of the most common reasons people try meditation. AYAVAYA’s anti-stress cabins offer a novel way to both manage stress and boost physical performance. Independent research has shown unanimously positive results for the more than 500 people who have tried AYAVAYA’s anti-stress cabin. Short, 20-minute-long practices of meditation have been proven to reduce stress-related health issues, such as anxiety, inflammation, post-traumatic stress disorder, and more.

According to the [American Institute of Stress, depression and anxiety cost the global economy approximately $1 trillion in lost productivity. A recent Stress in America 2022 survey from the American Psychological Association found more than a quarter of U.S. adults (27%) say that most days they are so stressed they can’t function. Adults also reported that stress has had an impact on their health; 76% of adults reported they had experienced at least one symptom in the last month as a result of stress.

The AYAVAYA anti-stress cabin has been successfully piloted at the BLUE Wellness Hotel by Fletcher Hotels in The Netherlands since October 2022, where the treatment has proven to be immensely popular. More than 200 paying customers have experienced the AYAVAYA treatment to date, and Fletcher Hotels plans to add more AYAVAYA anti-stress cabins to their other wellness resorts.

AYAVAYA is open to meeting with press, investors, and partners at CES in the mental health and healthtech space who are interested in scaling their effective anti-stress treatment to combat the global stress pandemic. Contact mailto:ayavaya@wearemgp.com [ayavaya@wearemgp.com __title__ null] to schedule a media interview and experience AYAVAYA first hand during CES 2023. Access the AYAVAYA press kit here.

About AYAVAYA

AYAVAYA is the creator of the patented, scientifically-validated AYAVAYA anti-stress cabin — the world’s most powerful way to combat stress with a simple, 20-minute treatment. The AYAVAYA cabin makes stress elimination and meditation available to anyone at the push of a button by combining knowledge from Eastern and Western medicine in four automated non-invasive treatments — sound therapy, aromatherapy, light therapy and Shirodhara, a water-based head treatment in which warm water is projected on the forehead with a specific flow, temperature and rhythm.

Founded in 2019, AYAVAYA is a privately held company based in The Hague, Netherlands. Follow AYAVAYA on LinkedIn and Twitter or learn more at https://www.ayavaya.co.

###

Share article on social media or email: